FORWARD CAD IDE Study
Part of paid clinical trials in La Jolla, California.
- Sponsor
- Shockwave Medical, Inc.
- Study ID
- NCT06662500
- Status
- Recruiting
Conditions
- Coronary Arterial Disease (CAD)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Intravascular Lithotripsy — DEVICEThe Shockwave Intravascular Lithotripsy (IVL) System with the Shockwave Javelin Coronary Catheter is intended to treat calcified stenosis, including calcified stenoses that are anticipated to exhibit resistance to balloon crossing, full dilatation or subsequent uniform coronary stent expansion.
Study Details
The FORWARD CAD IDE Study is a Prospective, Multicenter, Single-Arm, Investigational Device Exemption (IDE) Study conducted to assess the safety and effectiveness of the Shockwave Intravascular Lithotripsy (IVL) System with the Javelin Coronary IVL Catheter for the treatment of calcified, stenotic de novo coronary artery lesions prior to stenting.
Key Dates
- Start date
- Apr 4, 2025
- Status verified
- Feb 2026
- Primary completion
- Dec 8, 2025
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 408 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Shockwave Javelin Coronary IVL CatheterThe Shockwave Javelin Coronary IVL Catheter will be used to treat subjects with moderate-to-severely calcified, stenotic de novo coronary artery lesions presenting with stable angina or following stabilization after acute coronary syndrome (ACS) that are suitable for non-emergent percutaneous coronary intervention (PCI).
Primary Outcome Measure
Primary Safety Endpoint - Freedom from MACE within 30 days [ Time Frame: 30 Days ]
Central Contacts
- Randee Randoll408-577-7856
- Lesli DeSimone916-261-5189
Locations (28)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Scripps Health | La Jolla | California | 92037 | Matthew Price, M.D. (PRINCIPAL_INVESTIGATOR) |
| University of California, San Francisco | San Francisco | California | 94143 | Yousif Ahmad, PhD (PRINCIPAL_INVESTIGATOR) |
| South Denver Cardiology Associates, P.C | Littleton | Colorado | 80120 | Cinthia Bateman, MD (PRINCIPAL_INVESTIGATOR) |
| Hartford Hospital | Hartford | Connecticut | 06112 | Saurabh Joshi, MD (PRINCIPAL_INVESTIGATOR) |
| Medstar Washington Hospital Center | Washington D.C. | District of Columbia | 20010 | Ron Waksman, MD (PRINCIPAL_INVESTIGATOR) |
| The Cardiac and Vascular Institute | Gainesville | Florida | 32605 | Matheen Khuddus, MD (PRINCIPAL_INVESTIGATOR) |
| Emory University Hospital | Atlanta | Georgia | 30322 | William Nicholson, MD (PRINCIPAL_INVESTIGATOR) |
| Piedmont Heart Institute | Atlanta | Georgia | 30309 | Prashant Kaul, MD (PRINCIPAL_INVESTIGATOR) |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | Hector Tamez, MD (PRINCIPAL_INVESTIGATOR) |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | Kevin Croce, MD (PRINCIPAL_INVESTIGATOR) |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Suzanne Baron, MD (PRINCIPAL_INVESTIGATOR) |
| Minneapolis Heart Institute | Minneapolis | Minnesota | 55407 | Emmanouil Brilakis, MD (PRINCIPAL_INVESTIGATOR) |
| Columbia University Medical Center/New York Presbyterian Hospital | New York | New York | 10032 | Margaret McEntegart, M.D. (PRINCIPAL_INVESTIGATOR) |
| Lenox Hill Hospital | New York | New York | 10075 | Michael Kim, MD (PRINCIPAL_INVESTIGATOR) |
| NYU Langone Health | New York | New York | 10016 | Claudia Serrano-Gomez, M.D. (PRINCIPAL_INVESTIGATOR) |
| St. Francis Hospital & Heart Center | Roslyn | New York | 11576 | Ziad Ali, M.D. (PRINCIPAL_INVESTIGATOR) |
| NC Heart and Vascular Research, LLC | Raleigh | North Carolina | 27607 | James Zidar, MD (PRINCIPAL_INVESTIGATOR) |
| The Christ Hospital | Cincinnati | Ohio | 45219 | Jarrod Frizzel, MD (PRINCIPAL_INVESTIGATOR) |
| Providence St. Vincent | Portland | Oregon | 97225 | Jason Wollmuth, MD (PRINCIPAL_INVESTIGATOR) |
| Wellspan York Hospital | York | Pennsylvania | 17403 | Rhian Davies, DO (PRINCIPAL_INVESTIGATOR) |
| Centennial Heart | Nashville | Tennessee | 37203 | - |
| Baylor Scott & White Research Institute Dallas | Dallas | Texas | 75226 | Robert Stoler, MD (PRINCIPAL_INVESTIGATOR) |
| Houston Methodist Hospital | Houston | Texas | 77030 | Alpesh Shah, MD (PRINCIPAL_INVESTIGATOR) |
| Baylor Scott and White - The Heart Hospital Baylor Plano | Plano | Texas | 75093 | Srinivasa Potluri, MD (PRINCIPAL_INVESTIGATOR) |
| Intermountain Medical Center Heart Institute | Salt Lake City | Utah | 84111 | Mitul Patel, MD (PRINCIPAL_INVESTIGATOR) |
| Overlake Medical Center | Bellevue | Washington | 98004 | Robert Riley, MD (PRINCIPAL_INVESTIGATOR) |
| Swedish Medical | Seattle | Washington | 98122 | Christopher Brown, MD (PRINCIPAL_INVESTIGATOR) |
| University of Washington Medical Center | Seattle | Washington | 98195 | Lorenzo Azzalini, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in La Jolla, CA
Related Studies
- The Switching Antiplatelet-9 (SWAP-9) StudyPHASE4 · Recruiting · University of Florida · Jacksonville, Florida
- Focused Orticumab Research for Treating Inflammation in Coronary ArteriesPHASE2 · Recruiting · Abcentra · Los Angeles, California
- AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary LesionsRecruiting · Boston Scientific Corporation · La Jolla, California
- Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)PHASE4 · Recruiting · University of Florida · Jacksonville, Florida